Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The ARF tumour suppressor.

Stuart J Gallagher1, Richard F Kefford, Helen Rizos

  • 1Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, NSW 2145, Australia.

The International Journal of Biochemistry & Cell Biology
|April 8, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Emerging blood-based biomarkers for the detection of parenchymal brain metastasis: Current progress and future perspectives.

Neuro-oncology advances·2026
Same author

Stepping Up With Immune Checkpoint Blockade: More Combinations and Fewer Contraindications.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same author

Distinctive features of the tumor and immune microenvironment in glioblastoma.

NPJ precision oncology·2026
Same author

Targeting MEK in cancer and beyond: mechanistic insights and therapeutic opportunities.

Lancet (London, England)·2026
Same author

Correction: Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma.

Oncogenesis·2026
Same author

Translating ctDNA into cutaneous melanoma care: An international expert survey.

European journal of cancer (Oxford, England : 1990)·2026

The ARF tumor suppressor, altered in human cancer, regulates p53 stability. Its nucleolar localization under stress may coordinate cell cycle and survival, with sumoylation as a key pathway.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • The ARF tumor suppressor is encoded by the INK4a/ARF locus, frequently altered in human cancers.
  • ARF is upregulated by oncogenic stimuli and regulates p53 stability via mdm2 and ARF-BP1/Mule ubiquitin ligases.

Purpose of the Study:

  • To elucidate the role of ARF in cancer, focusing on its regulation, interactions, and cellular functions.
  • To investigate the significance of ARF's nucleolar localization and its potential as a reservoir for p53 induction.

Main Methods:

  • Analysis of ARF expression and its interactions with ubiquitin ligases (mdm2, ARF-BP1/Mule).
  • Investigation of ARF's subcellular localization, particularly its release from the nucleolus upon cellular stress.
  • Exploration of ARF's binding partners and the role of ARF-mediated sumoylation.

Related Experiment Videos

Main Results:

  • ARF's critical role in regulating p53 stability through interactions with mdm2 and ARF-BP1/Mule.
  • ARF is released from the nucleolus (bound to B23/nucleophosmin) by cellular stress signals.
  • ARF's nucleolar localization may serve as a reservoir for p53 induction and coordinate cell cycle and survival.

Conclusions:

  • ARF's nucleolar localization is a dynamic reservoir for rapid p53 induction and coordination of cellular processes.
  • ARF-mediated sumoylation may be a central mechanism underlying its diverse biological functions.
  • Understanding ARF's interactions and regulation is crucial for cancer therapy development.